home / stock / ocup / ocup news

OCUP News and Press, Ocuphire Pharma Inc Com From 11/08/22

Stock Information
Company Name: Ocuphire Pharma Inc Com
Stock Symbol: OCUP
Market: NASDAQ
Website: ocuphire.com
Menu
OCUP OCUP Quote OCUP Short OCUP News OCUP Articles OCUP Message Board
Get OCUP Alerts

News, Short Squeeze, Breakout and More Instantly...
OCUP - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday! Moving stocks this morning are earnings reports, stock of...
OCUP - Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties Strengthened Financial Position Supports Operations and APX3330 Program into 2025 Conference Call Tomorrow November 8, 2022 a...

OCUP - Ocuphire Pharma GAAP EPS of -$0.22 beats by $0.08

Ocuphire Pharma press release ( NASDAQ: OCUP ): Q3 GAAP EPS of -$0.22 beats by $0.08 . As of September 30, 2022, Ocuphire had cash and cash equivalents of approximately $13.9M. For further details see: Ocuphire Pharma GAAP EPS of -$0.22 beats by $0.08

OCUP - Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early 2023 FARMINGTON HILLS, Mich., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage op...
OCUP - Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the posi...

OCUP - Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance an...

OCUP - Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

FARMINGTON HILLS, Mich., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that CEO and ...
OCUP - Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease

Virtual Webinar to Take Place Friday, October 14 th @ 11 AM ET Topline Results from ZETA-1 Phase 2b Trial of APX3330 Expected Later in 4Q 2022 FARMINGTON HILLS, Mich., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophtha...

OCUP - Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team

FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has ...

OCUP - Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina So...
Previous 10 Next 10